Novo Nordisk settles patent infringement lawsuit with Novartis

Shortly before a trial was meant to begin, Novo Nordisk and Sandoz have settled a patent infringement case concerning diabetes drug Victoza, meaning the generic drugmaker isn’t allowed to launch its intended copy version before June 2024.
Photo: George Frey/Reuters/Ritzau Scanpix
Photo: George Frey/Reuters/Ritzau Scanpix
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen & catherine brett

The two pharmaceutical firms, Novo Nordisk and Novartis-owned Sandoz, have come to an agreement out of court, meaning that Sandoz will hold off on the launch of its generic version of the Danish firm’s blockbuster insulin analog, Victoza (liraglutide), industry media Fierce Pharma writes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading